Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2018 | Differentiating aggressive vs. non-aggressive prostate cancer: the MiCheck GPC1 biomarker test

The addition of a new prostate cancer diagnostic test to inform clinicians and patients prior to the decision to biopsy would be beneficial, in conjunction with the traditional measures of PSA and DRE. In this interview, Neal Shore, MD, FACS, of Carolina Urologic Research Center, Myrtle Beach, SC, gives us an overview of the MiCheck MIA test for differentiating aggressive from non-aggressive prostate cancer. Dr Shore explains how this test measures glypican-1 (GPC1) and related biomarker levels, and discusses how this parameter could impact the management of prostate cancer. This video was recorded at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA.